DK3077004T3 - Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML) - Google Patents
Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML) Download PDFInfo
- Publication number
- DK3077004T3 DK3077004T3 DK14808911.3T DK14808911T DK3077004T3 DK 3077004 T3 DK3077004 T3 DK 3077004T3 DK 14808911 T DK14808911 T DK 14808911T DK 3077004 T3 DK3077004 T3 DK 3077004T3
- Authority
- DK
- Denmark
- Prior art keywords
- aml
- myeloid leukemia
- acute myeloid
- combination treatment
- hitherto unknown
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361912152P | 2013-12-05 | 2013-12-05 | |
PCT/EP2014/076063 WO2015082384A1 (en) | 2013-12-05 | 2014-12-01 | Novel combination treatment for acute myeloid leukemia (aml) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3077004T3 true DK3077004T3 (da) | 2020-04-27 |
Family
ID=52014047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14808911.3T DK3077004T3 (da) | 2013-12-05 | 2014-12-01 | Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML) |
Country Status (31)
Country | Link |
---|---|
US (5) | US20160303158A1 (da) |
EP (1) | EP3077004B1 (da) |
JP (3) | JP6297695B2 (da) |
KR (1) | KR101862955B1 (da) |
CN (1) | CN105792847B (da) |
AR (1) | AR098576A1 (da) |
AU (1) | AU2014359422B2 (da) |
BR (1) | BR112016009669B1 (da) |
CA (1) | CA2926307C (da) |
CL (1) | CL2016001345A1 (da) |
CR (1) | CR20160173A (da) |
DK (1) | DK3077004T3 (da) |
EA (1) | EA201690785A1 (da) |
ES (1) | ES2785203T3 (da) |
HK (1) | HK1222808A1 (da) |
HR (1) | HRP20200566T1 (da) |
HU (1) | HUE049434T2 (da) |
IL (1) | IL244888B (da) |
LT (1) | LT3077004T (da) |
MA (1) | MA39040A1 (da) |
MX (1) | MX370618B (da) |
PE (1) | PE20160591A1 (da) |
PH (1) | PH12016500933A1 (da) |
PL (1) | PL3077004T3 (da) |
PT (1) | PT3077004T (da) |
RS (1) | RS60142B1 (da) |
SG (1) | SG11201604504VA (da) |
SI (1) | SI3077004T1 (da) |
TW (2) | TWI678204B (da) |
WO (1) | WO2015082384A1 (da) |
ZA (1) | ZA201602829B (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
KR20140100937A (ko) | 2011-10-18 | 2014-08-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
CA2926307C (en) * | 2013-12-05 | 2021-11-16 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
JP6971970B2 (ja) * | 2015-09-03 | 2021-11-24 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics, Inc. | ペプチド模倣大環状分子およびその使用 |
WO2017044633A1 (en) | 2015-09-10 | 2017-03-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of mcl-1 |
US10245258B2 (en) * | 2016-06-06 | 2019-04-02 | Celgene Corporation | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
JP6848047B2 (ja) * | 2016-08-08 | 2021-03-24 | フェイ シアオ, | スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用 |
SI3541387T1 (sl) | 2016-11-15 | 2021-08-31 | Novartis Ag | Odmerek in režim za zaviralce interakcije HDM2-P53 |
WO2018178925A1 (en) * | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
CN112294965B (zh) * | 2019-07-26 | 2023-03-14 | 苏州亚盛药业有限公司 | Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途 |
CA3218640A1 (en) * | 2021-05-13 | 2022-11-17 | Kanya Lakshmi RAJANGAM | Dosing regimens for cancer immunotherapy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2483084A1 (en) * | 2002-05-02 | 2003-11-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE102005012681A1 (de) * | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
CN101773408B (zh) * | 2010-01-15 | 2012-04-04 | 平荧 | 多功能排针结合电凝固技术提升下垂皮肤的装置 |
JP2013523820A (ja) * | 2010-04-09 | 2013-06-17 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | 疾患を処置する際に使用するためのmdm2阻害剤のバイオマーカー |
JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
CA2926307C (en) * | 2013-12-05 | 2021-11-16 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
US9657351B2 (en) * | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
-
2014
- 2014-12-01 CA CA2926307A patent/CA2926307C/en active Active
- 2014-12-01 BR BR112016009669-0A patent/BR112016009669B1/pt active IP Right Grant
- 2014-12-01 SI SI201431551T patent/SI3077004T1/sl unknown
- 2014-12-01 ES ES14808911T patent/ES2785203T3/es active Active
- 2014-12-01 PT PT148089113T patent/PT3077004T/pt unknown
- 2014-12-01 EP EP14808911.3A patent/EP3077004B1/en active Active
- 2014-12-01 SG SG11201604504VA patent/SG11201604504VA/en unknown
- 2014-12-01 KR KR1020167014756A patent/KR101862955B1/ko active IP Right Grant
- 2014-12-01 EA EA201690785A patent/EA201690785A1/ru unknown
- 2014-12-01 LT LTEP14808911.3T patent/LT3077004T/lt unknown
- 2014-12-01 WO PCT/EP2014/076063 patent/WO2015082384A1/en active Application Filing
- 2014-12-01 PE PE2016000615A patent/PE20160591A1/es not_active Application Discontinuation
- 2014-12-01 RS RS20200394A patent/RS60142B1/sr unknown
- 2014-12-01 CN CN201480066531.9A patent/CN105792847B/zh active Active
- 2014-12-01 MX MX2016007170A patent/MX370618B/es active IP Right Grant
- 2014-12-01 AU AU2014359422A patent/AU2014359422B2/en active Active
- 2014-12-01 DK DK14808911.3T patent/DK3077004T3/da active
- 2014-12-01 US US15/101,258 patent/US20160303158A1/en not_active Abandoned
- 2014-12-01 AR ARP140104469A patent/AR098576A1/es unknown
- 2014-12-01 HU HUE14808911A patent/HUE049434T2/hu unknown
- 2014-12-01 JP JP2016536634A patent/JP6297695B2/ja active Active
- 2014-12-01 PL PL14808911T patent/PL3077004T3/pl unknown
- 2014-12-03 TW TW107105068A patent/TWI678204B/zh active
- 2014-12-03 TW TW103142020A patent/TWI627954B/zh active
- 2014-12-04 US US14/560,086 patent/US9956243B2/en active Active
-
2016
- 2016-04-04 IL IL244888A patent/IL244888B/en active IP Right Grant
- 2016-04-14 CR CR20160173A patent/CR20160173A/es unknown
- 2016-04-25 ZA ZA2016/02829A patent/ZA201602829B/en unknown
- 2016-05-17 MA MA39040A patent/MA39040A1/fr unknown
- 2016-05-19 PH PH12016500933A patent/PH12016500933A1/en unknown
- 2016-06-02 CL CL2016001345A patent/CL2016001345A1/es unknown
- 2016-09-22 HK HK16111115.9A patent/HK1222808A1/zh unknown
-
2018
- 2018-02-21 JP JP2018028482A patent/JP6918724B2/ja active Active
-
2020
- 2020-02-19 US US16/794,991 patent/US20200253999A1/en not_active Abandoned
- 2020-04-07 HR HRP20200566TT patent/HRP20200566T1/hr unknown
-
2021
- 2021-02-05 JP JP2021017415A patent/JP2021091690A/ja active Pending
- 2021-05-19 US US17/324,248 patent/US20220031726A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/130,016 patent/US20230381215A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3077004T3 (da) | Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML) | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
DK3021838T3 (da) | Behandling af fedme | |
DK3458052T3 (da) | Kombinationsbehandling af cancer | |
HK1215790A1 (zh) | 治療骨髓性白血病的方法 | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
DK3052102T3 (da) | Sammensætninger til behandling af cancere | |
DK3532076T3 (da) | Immunterapeutiske behandlinger af tumorer | |
DK3063264T3 (da) | Tørring af mikroorganismer | |
CL2016000616A1 (es) | Compuestos heterocíclicos de n-acilimino. | |
FR3000700B1 (fr) | Revetement anti-foudre | |
DK2822301T3 (da) | Bestemmelse af individuelle HRTF | |
DK2976101T3 (da) | Behandlingsfremgangsmåde | |
DK3277813T3 (da) | Hidtil ukendt terapi | |
DK3253769T3 (da) | Hidtil ukendte polymorfer | |
DK2983652T3 (da) | Behandling af autismespektrumforstyrrelse | |
DK3041506T3 (da) | Behandlingsfremgangsmåde | |
NL301255I2 (nl) | Capromorelinetartraat | |
UA28455S (uk) | Тримач для лійки душу (mixxen mxd3001) | |
UA28876S (uk) | Тримач для лійки душу (mixxen mxd3001-l145) | |
UA28446S (uk) | Лійка для душу (віола mxz0048) | |
TH1501006732A (th) | สูตรตำรับพีมีแทรกเซด (pemetrexed) ที่มีความคงตัว |